| | | | | | | | | | | | | | | | | | | | |
| AGILENT TECHNOLOGIES, INC. |
| LIFE SCIENCES AND APPLIED MARKETS SEGMENT |
| (Unaudited) |
|
| All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments business from our Agilent CrossLab business segment to our Life Sciences and Applied Markets business segment and the movement of service revenue and cost of sales related to the acquisition of BioTek from our Life Sciences and Applied Markets business segment to our Agilent CrossLab business segment. |
| | | | | | |
| (In millions, except margins data) | FY21 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 923 | | $ | 881 | | $ | 897 | | $ | 962 | | $ | 3,663 | |
| Gross margin % | 60.3 | % | 59.9 | % | 60.4 | % | 59.9 | % | 60.2 | % |
| Research and development expenses | $ | 65 | | $ | 69 | | $ | 67 | | $ | 71 | | $ | 272 | |
| Selling, general and administrative expenses | $ | 227 | | $ | 233 | | $ | 225 | | $ | 230 | | $ | 915 | |
| Income from operations | $ | 265 | | $ | 226 | | $ | 250 | | $ | 276 | | $ | 1,017 | |
| Operating margin % | 28.6 | % | 25.7 | % | 27.9 | % | 28.7 | % | 27.8 | % |
| | | | | | |
| | | | | | |
| | FY20 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 816 | | $ | 701 | | $ | 733 | | $ | 865 | | $ | 3,115 | |
| Gross margin % | 60.4 | % | 59.0 | % | 59.7 | % | 59.2 | % | 59.6 | % |
| Research and development expenses | $ | 62 | | $ | 59 | | $ | 59 | | $ | 64 | | $ | 244 | |
| Selling, general and administrative expenses | $ | 215 | | $ | 196 | | $ | 192 | | $ | 217 | | $ | 820 | |
| Income from operations | $ | 215 | | $ | 159 | | $ | 187 | | $ | 231 | | $ | 792 | |
| Operating margin % | 26.4 | % | 22.7 | % | 25.5 | % | 26.7 | % | 25.4 | % |
| | | | | | |
| | | | | | |
| | FY19 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 785 | | $ | 710 | | $ | 729 | | $ | 803 | | $ | 3,027 | |
| Gross margin % | 61.5 | % | 60.3 | % | 60.5 | % | 60.6 | % | 60.7 | % |
| Research and development expenses | $ | 63 | | $ | 60 | | $ | 60 | | $ | 61 | | $ | 244 | |
| Selling, general and administrative expenses | $ | 206 | | $ | 203 | | $ | 203 | | $ | 208 | | $ | 820 | |
| Income from operations | $ | 214 | | $ | 165 | | $ | 178 | | $ | 218 | | $ | 775 | |
| Operating margin % | 27.3 | % | 23.2 | % | 24.5 | % | 27.2 | % | 25.6 | % |
| | | | | | |
Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, business exit and divestiture costs and special compliance costs.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
| | | | | | | | | | | | | | | | | | | | |
| AGILENT TECHNOLOGIES, INC. |
| DIAGNOSTICS AND GENOMICS SEGMENT |
| (Unaudited) |
|
| No change. Included to show our business segments structure in its entirety. |
| | | | | | |
| (In millions, except margins data) | FY21 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 294 | | $ | 315 | | $ | 346 | | $ | 341 | | $ | 1,296 | |
| Gross margin % | 51.6 | % | 53.4 | % | 53.5 | % | 52.5 | % | 52.8 | % |
| Research and development expenses | $ | 29 | | $ | 30 | | $ | 33 | | $ | 36 | | $ | 128 | |
| Selling, general and administrative expenses | $ | 68 | | $ | 69 | | $ | 74 | | $ | 72 | | $ | 283 | |
| Income from operations | $ | 55 | | $ | 69 | | $ | 78 | | $ | 71 | | $ | 273 | |
| Operating margin % | 18.6 | % | 21.9 | % | 22.6 | % | 20.8 | % | 21.0 | % |
| | | | | | |
| | | | | | |
| | FY20 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 249 | | $ | 263 | | $ | 241 | | $ | 294 | | $ | 1,047 | |
| Gross margin % | 51.7 | % | 55.1 | % | 49.8 | % | 50.9 | % | 51.9 | % |
| Research and development expenses | $ | 32 | | $ | 30 | | $ | 24 | | $ | 28 | | $ | 114 | |
| Selling, general and administrative expenses | $ | 63 | | $ | 58 | | $ | 55 | | $ | 62 | | $ | 238 | |
| Income from operations | $ | 34 | | $ | 57 | | $ | 41 | | $ | 60 | | $ | 192 | |
| Operating margin % | 13.5 | % | 21.6 | % | 17.2 | % | 20.3 | % | 18.3 | % |
| | | | | | |
| | | | | | |
| | FY19 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 235 | | $ | 254 | | $ | 263 | | $ | 269 | | $ | 1,021 | |
| Gross margin % | 54.0 | % | 54.8 | % | 55.7 | % | 54.0 | % | 54.7 | % |
| Research and development expenses | $ | 31 | | $ | 29 | | $ | 33 | | $ | 32 | | $ | 125 | |
| Selling, general and administrative expenses | $ | 63 | | $ | 61 | | $ | 64 | | $ | 60 | | $ | 248 | |
| Income from operations | $ | 33 | | $ | 49 | | $ | 50 | | $ | 53 | | $ | 185 | |
| Operating margin % | 14.0 | % | 19.3 | % | 19.1 | % | 19.7 | % | 18.2 | % |
| | | | | | |
Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, business exit and divestiture costs, NASD site costs and special compliance costs.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
| | | | | | | | | | | | | | | | | | | | |
| AGILENT TECHNOLOGIES, INC. |
| AGILENT CROSSLAB SEGMENT |
| (Unaudited) |
|
| All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments business from our Agilent CrossLab business segment to our Life Sciences and Applied Markets business segment and the movement of service revenue and cost of sales related to the acquisition of BioTek from our Life Sciences and Applied Markets business segment to our Agilent CrossLab business segment. |
| | | | | | |
| (In millions, except margins data) | FY21 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 331 | | $ | 329 | | $ | 343 | | $ | 357 | | $ | 1,360 | |
| Gross margin % | 46.8 | % | 45.3 | % | 46.6 | % | 48.3 | % | 46.8 | % |
| Research and development expenses | $ | 9 | | $ | 8 | | $ | 9 | | $ | 8 | | $ | 34 | |
| Selling, general and administrative expenses | $ | 70 | | $ | 72 | | $ | 67 | | $ | 70 | | $ | 279 | |
| Income from operations | $ | 76 | | $ | 69 | | $ | 84 | | $ | 94 | | $ | 323 | |
| Operating margin % | 23.1 | % | 21.0 | % | 24.4 | % | 26.3 | % | 23.8 | % |
| | | | | | |
| | | | | | |
| | FY20 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 292 | | $ | 274 | | $ | 287 | | $ | 324 | | $ | 1,177 | |
| Gross margin % | 46.2 | % | 46.4 | % | 47.6 | % | 47.3 | % | 46.9 | % |
| Research and development expenses | $ | 8 | | $ | 8 | | $ | 8 | | $ | 9 | | $ | 33 | |
| Selling, general and administrative expenses | $ | 65 | | $ | 58 | | $ | 58 | | $ | 66 | | $ | 247 | |
| Income from operations | $ | 62 | | $ | 61 | | $ | 71 | | $ | 78 | | $ | 272 | |
| Operating margin % | 21.1 | % | 22.3 | % | 24.7 | % | 24.2 | % | 23.1 | % |
| | | | | | |
| | | | | | |
| | FY19 |
| | Q1 | Q2 | Q3 | Q4 | Total |
| | | | | | |
| Revenue | $ | 264 | | $ | 274 | | $ | 282 | | $ | 295 | | $ | 1,115 | |
| Gross margin % | 45.7 | % | 46.1 | % | 46.5 | % | 47.8 | % | 46.6 | % |
| Research and development expenses | $ | 8 | | $ | 8 | | $ | 7 | | $ | 7 | | $ | 30 | |
| Selling, general and administrative expenses | $ | 63 | | $ | 61 | | $ | 62 | | $ | 61 | | $ | 247 | |
| Income from operations | $ | 50 | | $ | 57 | | $ | 62 | | $ | 73 | | $ | 242 | |
| Operating margin % | 19.0 | % | 20.9 | % | 21.8 | % | 24.6 | % | 21.7 | % |
| | | | | | |
Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, business exit and divestiture costs and special compliance costs.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
